Evidence map›Paper›PMID 32399196›Full record

ReviewF1000Research2020

Novel innovations in cell and gene therapies for spinal cord injury.

Mohammad-Masoud Zavvarian, Amirali Toossi, Mohamad Khazaei, James Hong, Michael Fehlings

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohammad-Masoud ZavvarianKrembil Research Institute, University Health Network, Toronto, Canada.
Amirali ToossiKrembil Research Institute, University Health Network, Toronto, Canada.
Mohamad KhazaeiKrembil Research Institute, University Health Network, Toronto, Canada.
James HongKrembil Research Institute, University Health Network, Toronto, Canada.
Michael FehlingsKrembil Research Institute, University Health Network, Toronto, Canada.ORCID 0000-0002-5722-6364

Funding

CIHR
6 · The paper itself

Abstract

Spinal cord injury (SCI) leads to chronic and multifaceted disability, which severely impacts the physical and mental health as well as the socio-economic status of affected individuals. Permanent disabilities following SCI result from the failure of injured neurons to regenerate and rebuild functional connections with their original targets. Inhibitory factors present in the SCI microenvironment and the poor intrinsic regenerative capacity of adult spinal cord neurons are obstacles for regeneration and functional recovery. Considerable progress has been made in recent years in developing cell and molecular approaches to enable the regeneration of damaged spinal cord tissue. In this review, we highlight several potent cell-based approaches and genetic manipulation strategies (gene therapy) that are being investigated to reconstruct damaged or lost spinal neural circuits and explore emerging novel combinatorial approaches for enhancing recovery from SCI.

Indexed as

Cell- and Tissue-Based TherapyGenetic TherapyHumansNeuronsRecovery of FunctionSpinal Cord InjuriesSpinal Cord Injury; Gene Therapy; Neuroregeneration; Stem Cells; Combinatorial Treatments

Identifiers

PMID32399196
PMCPMC7194487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.